Drug intelligence / Profile preview

AZD-8165

Development stage: Discontinued
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AZD‑8165 is a potent, selective, oral small molecule thrombin inhibitor that was developed by AstraZeneca for the treatment of thrombosis. It acts by inhibiting thrombin (F2), a serine protease central to the coagulation cascade and blood homeostasis. The drug reached phase 1 clinical trials for thrombosis but development has since been discontinued[1][3][4][7].

Other names: 1201686-72-7UNII-7WO8I5IY24UNII7WO8I5IY24UNII 7WO8I5IY241H-Pyrazole-5-carboxamide, N-((5-chloro-2-(1H-tetrazol-1-yl)phenyl)methyl)-1-((2R)-2-(4-fluorophenyl)-2-(1‑oxopropoxy)acetyl)-4,5-dihydro-, (5S)-

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on AZD-8165.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD-8165.

Explore the full profile